HRP20010744B1 - Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methyl aminothio carbonylamino sulfonylphenyl)ethyl)benzamide - Google Patents

Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methyl aminothio carbonylamino sulfonylphenyl)ethyl)benzamide

Info

Publication number
HRP20010744B1
HRP20010744B1 HR20010744A HRP20010744A HRP20010744B1 HR P20010744 B1 HRP20010744 B1 HR P20010744B1 HR 20010744 A HR20010744 A HR 20010744A HR P20010744 A HRP20010744 A HR P20010744A HR P20010744 B1 HRP20010744 B1 HR P20010744B1
Authority
HR
Croatia
Prior art keywords
methoxy
benzamide
chloro
ethyl
sodium salt
Prior art date
Application number
HR20010744A
Other languages
English (en)
Croatian (hr)
Inventor
Christian Englert Heinrich
Gerlach Uwe
Metzenthin Tobias
Schneider Harald
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20010744A2 publication Critical patent/HRP20010744A2/hr
Publication of HRP20010744B1 publication Critical patent/HRP20010744B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42Sulfonylthioureas; Sulfonylisothioureas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20010744A 1999-04-16 2001-10-15 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methyl aminothio carbonylamino sulfonylphenyl)ethyl)benzamide HRP20010744B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids
PCT/EP2000/002984 WO2000063167A1 (en) 1999-04-16 2000-04-04 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide

Publications (2)

Publication Number Publication Date
HRP20010744A2 HRP20010744A2 (en) 2003-04-30
HRP20010744B1 true HRP20010744B1 (en) 2010-08-31

Family

ID=7904803

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010744A HRP20010744B1 (en) 1999-04-16 2001-10-15 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methyl aminothio carbonylamino sulfonylphenyl)ethyl)benzamide

Country Status (33)

Country Link
US (1) US6723751B1 (ko)
EP (2) EP1173418B1 (ko)
JP (1) JP4662640B2 (ko)
KR (1) KR100700302B1 (ko)
CN (1) CN1168712C (ko)
AR (1) AR023479A1 (ko)
AT (2) ATE414059T1 (ko)
AU (1) AU773246B2 (ko)
BR (1) BR0010658A (ko)
CA (1) CA2370388C (ko)
CZ (1) CZ302459B6 (ko)
DE (3) DE19917233A1 (ko)
DK (1) DK1173418T3 (ko)
EE (1) EE04612B1 (ko)
ES (1) ES2251996T3 (ko)
HK (1) HK1046270B (ko)
HR (1) HRP20010744B1 (ko)
HU (1) HU229082B1 (ko)
IL (2) IL145921A0 (ko)
ME (1) MEP55708A (ko)
MX (1) MXPA01010275A (ko)
MY (1) MY122588A (ko)
NO (1) NO327798B1 (ko)
NZ (1) NZ514788A (ko)
PL (1) PL203809B1 (ko)
RS (1) RS50916B (ko)
RU (1) RU2235089C2 (ko)
SI (1) SI1173418T1 (ko)
SK (1) SK287175B6 (ko)
TR (2) TR200102993T2 (ko)
TW (1) TWI276622B (ko)
WO (1) WO2000063167A1 (ko)
ZA (1) ZA200108400B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542852A (en) * 2003-03-17 2008-09-26 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612724A1 (de) * 1993-02-23 1994-08-31 Hoechst Aktiengesellschaft Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe- Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika
WO2000015204A2 (en) * 1998-09-10 2000-03-23 Aventis Pharma Deutschland Gmbh Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612724A1 (de) * 1993-02-23 1994-08-31 Hoechst Aktiengesellschaft Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe- Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika
WO2000015204A2 (en) * 1998-09-10 2000-03-23 Aventis Pharma Deutschland Gmbh Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers

Also Published As

Publication number Publication date
AU773246B2 (en) 2004-05-20
MEP55708A (en) 2011-05-10
CZ302459B6 (cs) 2011-06-01
EP1637519A1 (en) 2006-03-22
HK1046270B (zh) 2005-03-11
EE04612B1 (et) 2006-04-17
PL351245A1 (en) 2003-04-07
SI1173418T1 (sl) 2006-02-28
RS50916B (sr) 2010-08-31
DE19917233A1 (de) 2000-10-19
PL203809B1 (pl) 2009-11-30
DE60024431D1 (en) 2006-01-05
MY122588A (en) 2006-04-29
JP2002542230A (ja) 2002-12-10
ZA200108400B (en) 2003-04-30
HUP0200791A3 (en) 2005-04-28
JP4662640B2 (ja) 2011-03-30
AU4542800A (en) 2000-11-02
NO20015014L (no) 2001-10-15
ES2251996T3 (es) 2006-05-16
EP1637519B1 (en) 2008-11-12
SK14582001A3 (sk) 2002-01-07
CA2370388A1 (en) 2000-10-26
DE60024431T2 (de) 2006-07-27
MXPA01010275A (es) 2003-07-21
TR200501142T2 (tr) 2005-08-22
ATE414059T1 (de) 2008-11-15
HK1046270A1 (en) 2003-01-03
NZ514788A (en) 2003-03-28
HUP0200791A2 (hu) 2002-07-29
ATE311364T1 (de) 2005-12-15
US6723751B1 (en) 2004-04-20
SK287175B6 (sk) 2010-02-08
AR023479A1 (es) 2002-09-04
WO2000063167A1 (en) 2000-10-26
HRP20010744A2 (en) 2003-04-30
TWI276622B (en) 2007-03-21
KR100700302B1 (ko) 2007-03-29
CN1354744A (zh) 2002-06-19
IL145921A0 (en) 2002-07-25
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
CN1168712C (zh) 2004-09-29
EP1173418A1 (en) 2002-01-23
IL145921A (en) 2006-07-05
DK1173418T3 (da) 2006-04-10
BR0010658A (pt) 2002-02-19
CA2370388C (en) 2009-10-13
CZ20013672A3 (cs) 2002-01-16
NO20015014D0 (no) 2001-10-15
TR200102993T2 (tr) 2002-03-21
NO327798B1 (no) 2009-09-28
DE60040811D1 (de) 2008-12-24
YU72001A (sh) 2004-07-15
HU229082B1 (hu) 2013-07-29
EP1173418B1 (en) 2005-11-30
EE200100532A (et) 2002-12-16

Similar Documents

Publication Publication Date Title
DE69017797D1 (de) Salzersatzgranulat.
KR930703311A (ko) 물질 p의 길항제인 n-알킬 퀴누클리디늄염
IS2217B (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni.
NO903391D0 (no) Vanndispergerbare granuler.
DE59200207D1 (de) Wasserzapfarmatur.
FI940355A0 (fi) Yhdisteet, joilla on angiotensiini II:ta vastustava vaikutus
DE69111646D1 (de) Wasserdispergierbare Granüle.
NO922167L (no) Aminodukter som korrosjonshemmere
HRP20010744B1 (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methyl aminothio carbonylamino sulfonylphenyl)ethyl)benzamide
EP1044953A4 (en) PROCESS FOR THE PREPARATION OF SALTS OF BETA-DICETO COMPOUNDS FROM ALKALINE EARTH METALS
FR2804956B1 (fr) Procede de preparation d'un compose polyaromatique
FR2759076B1 (fr) Procede de fabrication de petales de sel
ATE164154T1 (de) N,n-diethyl-8,8-dipropyl-2-azaspiro(4.5>decan-2 propan-amin dimaleatsalz
DZ2034A1 (fr) Sel de pyrrolydinyl-methyl-indole.
BR7101496U (pt) Dispositivo para producao de hipoclorito de sodio a partir de agua salgada
KR940026796U (ko) 은, 동이온발생식 물의 살균장치
JPS53135997A (en) Haloarylmalonamide oxacephalosporin
MX9202286A (es) Metodo para producir azidas de metales alcalinos.
FR2811664B1 (fr) Procede de preparation d'un compose polyaromatique
NO900650L (no) Fremgangsmaate for fremstilling av carbonatsalter av alkalimetaller.
ES270451Y (es) Camara para vigilancia perfeccionada.
EP0992237A3 (de) Neohesperidin dc als Kristallisationsinhibitor
BR7100085U (pt) Obturador para tubos
NO890929L (no) Styrekrets for saltvanncelle.
IT1161598B (it) Procedimento per la realizzazione di un elemento scatolare attrezzato,nonche' elemento scatolare cosi' ottenuto

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140311

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20150404